Skip to content

The impact of intraoperative esmolol on postoperative cardiovascular adverse events in patients with coronary artery disease undergoing non-cardiac surgery: A single-center, bidirectional cohort study

The impact of intraoperative esmolol on postoperative cardiovascular adverse events in patients with coronary artery disease undergoing non-cardiac surgery: A single-center, bidirectional cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116123
Enrollment
Unknown
Registered
2026-01-06
Start date
2024-11-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovascular adverse events after non-cardiac surgery

Interventions

The group that used esmolol during the operation:None
The group that did not use esmolol during the operation:None

Sponsors

Shandong Provincal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age >= 45 years; (2) ASA grade I - III; (3) Patients scheduled to undergo elective non-cardiac surgery under general anesthesia or regional anesthesia; (4) Preoperative coronary CT or coronary angiography shows coronary stenosis; (5) During the study period, if the same patient undergoes multiple surgeries, only the first surgery is included in the study; (6) Patients who have signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Use beta-blockers before the operation; (2) Those who need to avoid or use with caution esmolol: patients with sinus bradycardia, sick sinus syndrome, atrioventricular block, heart failure, cardiogenic shock, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, and those allergic to esmolol; (3) Patients with elevated troponin levels during the perioperative period due to non-ischemic diseases (such as sepsis, pulmonary embolism, cardiac cardioversion); (4) Patients with incomplete clinical data before or after the operation.

Design outcomes

Primary

MeasureTime frame
The main cardiovascular adverse event (MACE) occurred 30 days after the surgery;

Secondary

MeasureTime frame
The all-cause mortality rate, cardiovascular mortality rate, length of hospital stay, and length of stay in the ICU within 30 days after the surgery;Preoperative and postoperative levels of Mb, cTnT, cTnI, CK-MB, etc. of myocardial enzymes;The incidence of perioperative hypotension and bradycardia;The rates of readmission within 30 days after surgery, reoperation rate, and rate of coronary artery revascularization surgery;Acute kidney injury (AKI) and major adverse kidney events (MAKE) within 30 days after surgery;The incidence of postoperative cognitive dysfunction (POCD), bronchospasm, and the incidence of severe infection/sepsis;

Countries

China

Contacts

Public ContactGu Changping

Shandong Provincal Hospital

jsmggcp@163.com+86 158 0660 7957

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026